Canine Atopic Dermatitis

Canine Atopic Dermatitis


Global Canine Atopic Dermatitis Market to Reach US$2.5 Billion by 2030

The global market for Canine Atopic Dermatitis estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2023-2030. Glucocorticoids, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Antihistamines segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$385.7 Million While China is Forecast to Grow at 12.0% CAGR

The Canine Atopic Dermatitis market in the U.S. is estimated at US$385.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$636.3 Million by the year 2030 trailing a CAGR of 12.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Canine Atopic Dermatitis Market – Key Trends & Drivers Summarized

Why Is Canine Atopic Dermatitis Gaining Attention in Veterinary Healthcare?

Canine atopic dermatitis (CAD) is one of the most common skin disorders affecting dogs, characterized by chronic inflammation and itching caused by environmental allergens such as pollen, dust mites, and molds. The condition is gaining significant attention in veterinary healthcare due to its increasing prevalence and its impact on dogs’ quality of life. Canine atopic dermatitis often leads to persistent itching, scratching, and skin infections, which can cause significant discomfort and require long-term management. Veterinary experts estimate that 10% to 15% of dogs globally suffer from some form of atopic dermatitis, with certain breeds like Golden Retrievers, Bulldogs, and German Shepherds being particularly prone to the condition. Pet owners are becoming more aware of canine skin health, and there is a growing demand for effective treatments that address both the symptoms and the underlying causes of CAD. The veterinary healthcare industry has responded by developing a range of therapies, including corticosteroids, antihistamines, immune-modulating drugs, and specialized diets designed to reduce allergic reactions. As pet ownership rises, particularly in developed countries where pets are considered part of the family, more resources are being devoted to the diagnosis, treatment, and management of chronic conditions like CAD.

How Are Innovations in Diagnosis and Treatment Improving Canine Atopic Dermatitis Care?

Advancements in diagnostic tools and treatments are revolutionizing the management of canine atopic dermatitis. Veterinarians are now using more precise diagnostic methods, such as intradermal skin testing and allergen-specific immunotherapy (ASIT), to identify the specific allergens triggering a dog`s symptoms. These diagnostic techniques allow for more targeted and personalized treatments, which can significantly improve outcomes. In particular, ASIT involves desensitizing dogs to the allergens they are allergic to, reducing their allergic reactions over time. This form of treatment is particularly beneficial for dogs that do not respond well to conventional therapies or have severe, recurring symptoms. On the treatment front, there have been notable advancements in the development of biologic therapies and immunomodulators. Cytopoint, for instance, is a monoclonal antibody that targets interleukin-31 (IL-31), a key protein involved in the itch signal, and has gained popularity for its ability to provide long-lasting relief from itching with fewer side effects compared to traditional corticosteroids. Similarly, Apoquel, an immune-modulating drug, has been widely adopted for its effectiveness in reducing inflammation and itchiness in dogs with atopic dermatitis. These treatments, which offer more targeted approaches with fewer side effects, represent significant progress in managing a condition that often requires lifelong therapy.

How Are Changing Consumer Behaviors Shaping the Canine Atopic Dermatitis Market?

As pet ownership trends evolve, consumer behaviors are increasingly influencing the canine atopic dermatitis market. Pet owners today are more invested in their pets` health and well-being, often seeking premium healthcare solutions and proactive treatments. This growing trend of "humanization" of pets is driving demand for advanced and innovative therapies that not only alleviate symptoms but also improve the overall quality of life for pets. As a result, veterinary healthcare providers are witnessing a rising demand for personalized treatments, allergen-free diets, and even alternative therapies such as acupuncture and herbal treatments to manage canine atopic dermatitis.

Another key factor shaping the market is the increased use of telemedicine and digital health platforms in veterinary care. Pet owners are turning to online platforms to consult with veterinary dermatologists and access information on how to better manage chronic conditions like CAD. This shift toward digital healthcare services is making it easier for pet owners to receive timely advice and access specialized care that may not be readily available locally. Moreover, the demand for natural and organic pet products is influencing the development of hypoallergenic pet foods and topical treatments, which cater to owners seeking gentler, non-pharmaceutical approaches to managing their dogs’ skin conditions.

Growth in the Canine Atopic Dermatitis Market Is Driven by Several Factors

Growth in the canine atopic dermatitis market is driven by several factors, including advancements in veterinary healthcare, the rising awareness among pet owners, and the increasing demand for innovative treatments. Technological progress in diagnostics, particularly in identifying specific allergens through skin testing and serum-based tests, has enabled veterinarians to offer more targeted and effective treatments for dogs with atopic dermatitis. The introduction of biologic therapies, like monoclonal antibodies and immune modulators, has provided pet owners with more options for long-term management of the condition, reducing the need for steroids and other drugs that can have severe side effects when used over extended periods. Another key growth driver is the rising number of pet owners who are more invested in ensuring their pets receive high-quality healthcare. This demographic shift, particularly in developed regions, has led to increased spending on veterinary services and medications, including those related to skin conditions like CAD. The growing interest in hypoallergenic diets and allergen-free pet products is also boosting the market for dietary interventions and topical treatments aimed at controlling flare-ups. Additionally, the integration of telemedicine in veterinary care is making it easier for pet owners to manage chronic conditions like CAD, with online consultations offering guidance on treatment plans and symptom management. These factors, along with the increasing focus on pet wellness and preventative care, are expected to continue driving the expansion of the canine atopic dermatitis market.

Select Competitors (Total 42 Featured) -
  • AB Science
  • Boehringer Ingelheim
  • Ceva
  • Elanco
  • Elanco Animal Health
  • indred Biosciences Inc.
  • Kindred Biosciences
  • Novartis
  • Toray Industries
  • Virbac
  • Zoetis


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Canine Atopic Dermatitis – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Canine Atopic Dermatitis Globally Drives Demand for Effective Treatments
Advances in Veterinary Dermatology Enhance Understanding and Management of Canine Atopic Dermatitis
Development of Novel Therapeutics for Canine Atopic Dermatitis Based on Human Atopic Dermatitis Research
Increased Pet Ownership and Spending on Pet Healthcare Propel Market Growth for Canine Dermatitis Products
Growing Awareness Among Pet Owners About Canine Allergies and Their Management Necessitates Specialized Care
Impact of Environmental Changes on the Incidence and Severity of Canine Atopic Dermatitis
Expansion of Pet Insurance and Coverage for Dermatological Conditions Improves Access to Treatments
Adoption of Immunotherapy and Biological Drugs in Veterinary Medicine Opens New Treatment Avenues
Technological Advancements in Diagnostic Tools for Early Detection of Atopic Dermatitis in Dogs
Role of Diet and Nutrition in Managing Canine Atopic Dermatitis Promotes Specialized Pet Food Market
Increased Use of Telemedicine and Digital Tools for Remote Diagnosis and Monitoring of Canine Health
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Canine Atopic Dermatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Glucocorticoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Glucocorticoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Glucocorticoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Antihistamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for MAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for MAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for MAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 28: World Canine Atopic Dermatitis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
JAPAN
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
CHINA
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
EUROPE
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Canine Atopic Dermatitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
FRANCE
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
GERMANY
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
UNITED KINGDOM
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Canine Atopic Dermatitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
AUSTRALIA
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
INDIA
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
LATIN AMERICA
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Canine Atopic Dermatitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
MIDDLE EAST
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Canine Atopic Dermatitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
AFRICA
Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings